Effect of mutation K85R on GSK-3beta: Molecular dynamics simulation

Prior research has shown that glycogen synthase kinase-3 (GSK-3) regulates glycogen synthesis and signaling pathways. It is already known that GSK-3 is a key target in diseases like diabetes and Alzheimer's. However, the role of conserved residues like Lys85 in enzyme activity remains unclear. No prior work had resolved how specific mutations at Lys85 affect structural and functional properties of GSK-3beta. This gap motivated a detailed computational analysis of the K85R mutation. Researchers have not yet fully explained how hydrogen bonds and salt bridges at Lys85 influence ATP binding and substrate groove conformation. That uncertainty drove the need for molecular dynamics simulations to explore the effects of this mutation. This paper's contribution is to clarify the structural consequences of K85R in GSK-3beta.

The aim of this study is to investigate how the K85R mutation affects GSK-3beta function. Researchers focused on the conserved residue Lys85 and its role in enzyme activity. They sought to determine if the K85R mutation disrupts hydrogen bonds and salt bridges critical to ATP binding. The study aimed to assess conformational changes in key residues like Phe93 and Glu211. The researchers also wanted to evaluate how these changes might impact the substrate binding groove. They tested whether the mutation leads to less energy-favorable interactions using MM-GBSA calculations. The goal was to link structural changes to enzyme inhibition. This work provides a computational framework for understanding how Lys85 mutations affect GSK-3beta activity.

The researchers used molecular dynamics simulations to model the K85R mutation in GSK-3beta. They analyzed hydrogen bond interactions between Lys85 and ATP before and after mutation. The study evaluated the formation of a salt bridge between Lys85 and Glu97. Structural changes in Phe93, Arg96, and Glu211 were tracked over simulation time. The team used MM-GBSA calculations to estimate binding free energy changes. They compared the wild-type and mutant structures to identify conformational differences. The simulations focused on the substrate binding groove and its flexibility. This approach allowed the authors to link structural alterations to functional consequences.

The K85R mutation caused the loss of one hydrogen bond between Lys85 and ATP. The salt bridge between Lys85 and Glu97 could not form in the mutant. Phe93, Arg96, and Glu211 showed altered conformations in the mutant structure. These changes affected the shape of the substrate binding groove. The MM-GBSA calculations suggested a less energy-favorable complex in the mutant. The mutant enzyme exhibited reduced stability in ATP binding interactions. Structural analysis confirmed that the mutation disrupts key interactions. These findings suggest that the K85R mutation may inhibit GSK-3beta activity.

The authors propose that the K85R mutation disrupts hydrogen bonds and salt bridges essential for ATP binding. They suggest that the mutation leads to conformational changes in key residues. The altered structure of the substrate binding groove may inhibit enzyme activity. MM-GBSA results support the idea that the mutant complex is less stable. The findings indicate that Lys85 is important for maintaining active enzyme conformation. The study highlights the role of conserved residues in enzyme function. These results may inform future drug design targeting GSK-3beta. The authors conclude that structural changes from the mutation correlate with reduced activity.